Objective To explore the correlation between anxiety and depression, treatment compliance and social support level in elderly patients with coronary heart disease. Methods A cross-sectional study was conducted on 325 patients with coronary heart disease who were treated in this hospital from June 2023 to June 2025 Pearson correlation analysis was used to examine the correlations between the level of social support [Social Support Rating Scale (SSRS)] and treatment compliance [12-item Medication Compliance Scale (MAS)], anxiety [Hamilton Anxiety Scale (HAMA)], and depression [Hamilton Depression Scale (HAMD)]. Logistic regression analysis was conducted to analyze the factors related to treatment compliance of coronary heart disease. Results SSRS score was positively associated with MAS score, and negatively correlated with HAMA score and HAMD score in patients with coronary heart disease (P<0.05). Logistic regression analysis suggested that age, education level, living alone, cardiac function grading, mini-mental state examination scale score, SSRS score, HAMA score and HAMD score were independently correlated with treatment compliance in patients with coronary heart disease (P<0.05). Conclusion The level of social support in patients with coronary heart disease is positively correlated with treatment compliance, and negatively correlated with anxiety and depression, and social support level, anxiety and depression are independent related factors affecting treatment compliance.

Objective:To summarize the clinical feature of functional distant metastasis (DM) of differentiated thyroid cancer (DTC) and observe the efficacy of 131I treatment. Methods:Between August 2008 and January 2021, a total of 13 DTC patients (4 males, 9 females; age 26-75 years) with functional DM from Henan Provincial People′s Hospital were retrospectively analyzed. Clinical data of patients were collected, including pathological type, metastasis size, metastasis location, and thyroid stimulating hormone (TSH) before the first 131I treatment. Efficacy of 131I treatment in patients with functional DM-DTC was evaluated by response evaluation criteria in solid tumors (RECIST) 1.1 and thyroglobulin (Tg). Complete remission (CR) and partial remission (PR) were considered as effective. Wilcoxon signed rank test was used to analyze the maximum diameter change of metastatic lesions before and after 131I treatment. Results:Among 13 DM-DTC patients, 8 were follicular thyroid cancer (FTC), 5 were papillary thyroid cancer (PTC). Metastasis lesions were mainly located in lungs ( n=12) and bones ( n=6). There were 12 patients with maximum metastasis diameter ≥1 cm, and 3 patients with TSH≥30 mU/L before the first 131I treatment. Nine patients were assessed as PR by RECIST 1.1, 3 patients were assessed as CR by RECIST 1.1 and the value of Tg, and 1 patient was assessed as PR by the changing of Tg. The effective rate of 131I treatment for patients with functional DM-DTC was 13/13. The maximum metastasis diameter was significantly decreased after 131I treatment (2.6(1.6, 3.3) vs 1.2(0.1, 2.2) cm; z=-3.06, P=0.002). Conclusion:Patients with functional DM-DTC are characterized by high proportion of FTC and the maximum metastasis diameter ≥1 cm, low proportion of TSH ≥30 mU/L before the first 131I treatment, and high effective rate of 131I treatment.

Objective: To investigate the regularity and clinical significance of abnormal bone uptake of ⁹⁹Tc^m-methylene bisphosphonate (MDP) in benign and malignant lesions. Methods: A retrospective analysis was performed on 266 patients (132 males, 134 females, age range: 8-85 years) with abnormal uptake of ⁹⁹Tc^m-MDP in extraosseous tissues from September 2015 to March 2018. The final diagnosis of abnormal uptake was made according to the histopathology, laboratory and related imaging examination (CT, MRI, ultrasound, SPECT/CT or PET/CT imaging) results within 2 weeks after ⁹⁹Tc^m-MDP imaging. Regularity of abnormal ⁹⁹Tc^m-MDP uptake was comprehensively analyzed. Differences between benign and malignant groups were compared by χ² test or Fisher exact test. Results: Abnormal ⁹⁹Tc^m-MDP uptake in extraosseous tissues in 232 patients (87.2%, 232/266) were confirmed as malignant lesions and those in 34 patients (12.8%, 34/266) were benign. There were no significant differences in gender (χ²=0.611, P>0.05), age (P=0.584), and location (P=0.118) between benign and malignant lesions, but the involvement was significantly different (χ²=19.515, P<0.05). There were significant differences between single focus and diffuse foci of single organ, diffuse foci of single organ and multiple foci groups (χ²=8.959, 19.325, both P<0.01). Conclusions The detection rate of malignancy among foci with abnormal ⁹⁹Tc^m-MDP uptake in extraosseous tissues is high, and the malignancy may relate with the involvement of foci. When extraosseous uptake is found, clinical information and related examination results should be comprehensively analyzed and the malignancy should be taken into account.